PSN-632,408

PSN-632,408 is a drug that was developed by Pfizer for the treatment of pain. It acts as a selective agonist for the cannabinoid receptor CB2, with much lower affinity for the psychoactive CB1 receptor.

Pharmacology

PSN-632,408 is a selective agonist for the cannabinoid receptor CB2, with a binding affinity of 32.2 nM at CB2 and 1,132 nM at CB1, giving it around 35x selectivity for CB2. This makes it useful for the treatment of pain, as activation of CB2 receptors does not produce psychoactive effects, and so does not lead to the side effects associated with activation of CB1.

Clinical trials

PSN-632,408 has been through Phase I clinical trials in humans, and was found to be well tolerated with no serious adverse effects reported. However, it has not proceeded to Phase II trials, and so is not currently approved for use in humans.

See also

• Cannabinoid receptor
• Cannabinoid receptor agonist
• Pfizer

References

PSN-632,408 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski